Φλεβάρης των φλεβών κουτσό ποτάμι κυλάει σαν παράπονο στο τζάμι Σαββάτο των ψυχών κρυφά δακρύζει στα σπίτια των απόντων φτερουγίζει Μάρωνος και Νικηφόρου και Ανθούσης ,Τελεσφόρου Χαραλάμπους και Βλασσίου, Κασσιανού και Θαλασσίου Τρύφωνος και Παγκρατίου, ήλιος του μεσονυχτίου φέγγει απότομα και λιώνει, της Υπαπαντής το χιόνι… Η νύχτα Φαρισαίου και Τελώνου αθώος ξένου αίματος και φόνου ανάβει της αγάπης τα λυχνάρια και τα παλιά διαβάζει συναξάρια

“Φλεβάρης των φλεβών”-Παντελής Θαλασσινός
Στίχοι :Ηλίας Κατσούλης, μουσική και ερμηνεία Παντελής Θαλασσινός, από το cd ”Καλαντάρι”

Ο Αύγουστος του έκλεψε μια μέρα
την ύψωσε πανάκι σε μπρατσέρα
μια άλλη χρόνους τέσσερις χαμένη
σαν άσωτη επιστρέφει, μα δε μένει.

Φλεβάρης των φλεβών κουτσό ποτάμι
κυλάει σαν παράπονο στο τζάμι
Σαββάτο των ψυχών κρυφά δακρύζει
στα σπίτια των απόντων φτερουγίζει

Μάρωνος και Νικηφόρου και Ανθούσης ,Τελεσφόρου
Χαραλάμπους και Βλασσίου, Κασσιανού και Θαλασσίου
Τρύφωνος και Παγκρατίου, ήλιος του μεσονυχτίου
φέγγει απότομα και λιώνει, της Υπαπαντής το χιόνι…

Η νύχτα Φαρισαίου και Τελώνου
αθώος ξένου αίματος και φόνου
ανάβει της αγάπης τα λυχνάρια
και τα παλιά διαβάζει συναξάρια

Μάρωνος και Νικηφόρου και Ανθούσης ,Τελεσφόρου
Χαραλάμπους και Βλασσίου, Κασσιανού και Θαλασσίου
Τρύφωνος και Παγκρατίου, ήλιος του μεσονυχτίου
φέγγει απότομα και λιώνει, της Υπαπαντής το χιόνι…

Τρύφωνος και Παγκρατίου, ήλιος του μεσονυχτίου
φέγγει απότομα και λιώνει, της Υπαπαντής το χιόνι…

(την ιδέα για το βίντεο την πήρα από το oikohouse της Μέλιας)

Centers for Disease Control and Prevention (CDC) : National Black HIV/AIDS Awareness Day — February 7, 2019 HIV Partner Service Delivery Among Blacks or African Americans — United States, 2016 Shubha Rao, MPH; Wei Song, PhD; Mesfin S. Mulatu, PhD; et al. The figure shows an African American doctor explaining a diagnosis to a patient. In 2017, the rate of diagnosis of new human immunodeficiency virus infection among blacks/African Americans was approximately eight times that of non-Hispanic whites. Use of Toothpaste and Toothbrushing Patterns Among Children and Adolescents — United States, 2013–2016 Gina Thornton-Evans, DDS; Michele L. Junger, DDS; Mei Lin, MD; et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018 Elisabeth M. Hesse, MD; Tom T. Shimabukuro, MD; John R. Su, MD; et al. Notes From The Field: Mumps Outbreak in a Recently Vaccinated Population — Kosrae, Federated States of Micronesia, August–December, 2017 Susannah L. McKay, PhD; Afeke Kambui, MPH; Livinson A. Taulung, DCHMS; et al. QuickStats: Percentage of Adults Aged ≥18 Years Who Were Prescribed Medication in the Past 12 Months, by Sex and Age Group — National Health Interview Survey, 2017

MMWR Weekly (No. 4) PDF of this issue

• National Black HIV/AIDS Awareness Day — February 7, 2019
  
• HIV Partner Service Delivery Among Blacks or African Americans — United States, 2016
  Shubha Rao, MPH; Wei Song, PhD; Mesfin S. Mulatu, PhD; et al.
  
  
  In 2017, the rate of diagnosis of new human immunodeficiency virus infection among blacks/African Americans was approximately eight times that of non-Hispanic whites.
  
• Use of Toothpaste and Toothbrushing Patterns Among Children and Adolescents — United States, 2013–2016
  Gina Thornton-Evans, DDS; Michele L. Junger, DDS; Mei Lin, MD; et al.
  
• Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
  Elisabeth M. Hesse, MD; Tom T. Shimabukuro, MD; John R. Su, MD; et al.
  
• Notes From The Field: Mumps Outbreak in a Recently Vaccinated Population — Kosrae, Federated States of Micronesia, August–December, 2017
  Susannah L. McKay, PhD; Afeke Kambui, MPH; Livinson A. Taulung, DCHMS; et al.
  
• QuickStats: Percentage of Adults Aged ≥18 Years Who Were Prescribed Medication in the Past 12 Months, by Sex and Age Group — National Health Interview Survey, 2017

MMWR Masthead

Stay up-to-date with the "voice of CDC" by downloading the MMWR Express app for fast access to MMWR:
https://www.cdc.gov/mmwr/mmwr_mobileapps.html.

Department of Health and Human Services
Centers for Disease Control and Prevention

Proton pump inhibitors: Risk of Developing Alzheimer's Disease or Vascular Dementia,Cardiovascular and non-cardiovascular concerns,

Trends Cardiovasc Med. 2018 Oct 21. pii: S1050-1738(18)30243-3. doi: 10.1016/j.tcm.2018.10.008. [Epub ahead of print]
Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?
Corsonello A1, Lattanzio F2.
Author information
1
Italian National Research Center on Aging (IRCCS INRCA), Ancona, Cosenza, Italy. Electronic address: andrea_corsonello@tin.it.
2
Italian National Research Center on Aging (IRCCS INRCA), Ancona, Cosenza, Italy.
Abstract
The introduction of proton pump inhibitors (PPIs) has been a cornerstone in the treatment of acid-related disorders, such as gastroesophageal reflux and peptic ulcer, and their use has increased rapidly during the last decades. Being highly lipophilic drugs, they may potentially affect several pathophysiological pathways involved in cardiovascular and kidney morbidity, immune response and infections, absorption of selected nutrients, bone metabolism and cognitive function. Clinical epidemiology evidence coming from well-designed analyses of observational data consistently reported that long-term use of PPIs may increase the risk of cardiovascular events among patients treated with thienopyridines, tubular-interstitial nephritis and chronic kidney disease, hypomagnesemia, and fractures. Conversely, currently available evidence about the impact of PPIs on cardiovascular risk among patients not treated with thienopyridines, infections, nutritional disorders, cognitive impairment and dementia is limited by confounding. Given that randomized controlled trials investigating these issues are unlikely to be realized, the application of modern pharmacoepidemiology principles is expected to mitigate limitations of observational studies while addressing these relevant knowledge gaps. Meanwhile, physicians should be aware of potential issues related to long-term use of PPIs and weigh benefits of PPI therapy for appropriate indications along with the likelihood of the potential risks. A deprescription trial should be considered for all PPI users who do not have definite indications for long-term therapy.

Copyright © 2018 Elsevier Inc. All rights reserved.

KEYWORDS:
Clinical pharmacology; Proton pump inhibitors; Safety

PMID: 30389278 DOI: 10.1016/j.tcm.2018.10.008

Drug Saf. 2018 Dec;41(12):1387-1396. doi: 10.1007/s40264-018-0704-9.
Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis.
Imfeld P1,2, Bodmer M3, Jick SS4,5, Meier CR6,7,8.
Author information
1
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
2
Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
3
Medical Clinic, Zuger Kantonsspital, Baar, Switzerland.
4
Boston Collaborative Drug Surveillance Program, Lexington, MA, USA.
5
Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
6
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. christoph.meier@usb.ch.
7
Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. christoph.meier@usb.ch.
8
Boston Collaborative Drug Surveillance Program, Lexington, MA, USA. christoph.meier@usb.ch.
Abstract
INTRODUCTION:
Long-term use of proton pump inhibitors (PPIs) has been associated with an increased risk of Alzheimer's disease (AD) in observational studies. The role of exposure duration, and whether this applies to other dementia subtypes, has not been explored in these studies.

OBJECTIVE:
The aim was to study the association between long-term use of PPIs (or of histamine-2 receptor antagonists [H2RAs], as a negative control) and the risk of developing AD or vascular dementia (VaD).

METHODS:
We conducted a case-control analysis on the UK-based Clinical Practice Research Datalink (CPRD). We identified 41,029 patients aged ≥ 65 years with newly diagnosed AD or VaD between 1998 and 2015 and matched them 1:1 to dementia-free controls on age, sex, calendar time, general practice, and number of years of recorded history. We applied conditional logistic regression analyses to calculate adjusted odds ratios (aORs), with 95% confidence intervals (CIs), of developing AD or VaD in relation to previous use of PPIs or H2RAs, categorized by exposure duration.

RESULTS:
As compared to non-use, long-term PPI use (≥ 100 prescriptions) was not associated with an increased risk of developing AD (aOR 0.88, 95% CI 0.80-0.97) or VaD (aOR 1.18, 95% CI 1.04-1.33). Neither was long-term use of H2RAs (≥ 20 prescriptions) associated with an increased risk of developing AD (aOR 0.94, 95% CI 0.87-1.02) or VaD (aOR 0.99, 95% CI 0.89-1.10).

CONCLUSION:
In this large, case-control analysis, we did not find any evidence for an increased risk of either AD or VaD related to PPI or H2RA use.

Comment in
Comment on "Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis". [Drug Saf. 2018]
Authors' Reply to Katsuhiro Toda's Comment on "Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis". [Drug Saf. 2018]
PMID: 30146658 DOI: 10.1007/s40264-018-0704-9

Age, vascular health, and Alzheimer disease biomarkers

Ann Neurol. 2017 Nov;82(5):706-718. doi: 10.1002/ana.25071. Epub 2017 Oct 26.
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample.
Vemuri P1, Lesnick TG2, Przybelski SA2, Knopman DS3, Lowe VJ1, Graff-Radford J3, Roberts RO2, Mielke MM2,3, Machulda MM4, Petersen RC3, Jack CR Jr1.
Author information
1
Department of Radiology, Mayo Clinic, Rochester, MN.
2
Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
3
Department of Neurology, Mayo Clinic, Rochester, MN.
4
Department of Psychology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE:
To investigate the associations between age, vascular health, and Alzheimer disease (AD) imaging biomarkers in an elderly sample.

METHODS:
We identified 430 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) scans from the population-based Mayo Clinic Study of Aging. A subset of 329 individuals had fluorodeoxyglucose (FDG) PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from health care records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from Pittsburgh compound B PET, entorhinal cortex tau uptake (ERC-tau) from tau-PET, and neurodegeneration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology. We dichotomized participants into CMC = 0 (CMC- ) versus CMC > 0 (CMC+ ) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects.

RESULTS:
CMC+ participants had significantly greater neurodegeneration than CMC- participants but did not differ by amyloid or ERC-tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-tau.

INTERPRETATION:
Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. Ann Neurol 2017;82:706-718.

© 2017 American Neurological Association.

PMID: 29023983 PMCID: PMC5696029 DOI: 10.1002/ana.25071

Ann Neurol. Author manuscript; available in PMC 2018 Nov 1.

Published in final edited form as:

Ann Neurol. 2017 Nov; 82(5): 706–718.

Published online 2017 Oct 26. doi: 10.1002/ana.25071

PMCID: PMC5696029

NIHMSID: NIHMS911269

PMID: 29023983

Age, Vascular Health, and Alzheimer’s disease Biomarkers in an Elderly Sample

Prashanthi Vemuri,1 Timothy G. Lesnick,2 Scott A. Przybelski,2 David S. Knopman,3 Val J. Lowe,1Jonathan Graff-Radford,3 Rosebud O. Roberts,2 Michelle M. Mielke,2,3 Mary M. Machulda,4 Ronald C. Petersen,3and Clifford R. Jack, Jr1

Author information Copyright and License information Disclaimer

1Department of Radiology, Mayo Clinic Rochester, MN

2Health Sciences Research, Mayo Clinic Rochester, MN

3Department of Neurology, Mayo Clinic Rochester, MN

4Department of Psychology, Mayo Clinic Rochester, MN

Corresponding Author: Prashanthi Vemuri, Ph.D., Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, Phone: +1 507 538 0761, Fax:+1 507 284 9778, ude.oyam@ihtnahsarp.irumev

The publisher's final edited version of this article is available at Ann Neurol

See other articles in PMC that cite the published article.

Associated Data

Supplementary Materials

Supp info.

NIHMS911269-supplement-Supp_info.docx (42K)

GUID: 35D44FAE-B757-4EBB-AA2F-3B36BBACD822

Go to:

Abstract

OBJECTIVE

To investigate the associations between age, vascular health, and Alzheimer’s disease (AD) imaging biomarkers in an elderly sample.

METHODS

We identified 430 individuals along the cognitive continuum aged>60 years with amyloid-PET, Tau-PET, and MRI scans from the population-based Mayo Clinic Study of Aging. A subset of 329 individuals had FDG-PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from healthcare records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac-arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from PiB-PET, entorhinal cortex tau uptake (ERC-tau) from Tau-PET, and neurodegeneration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology. We dichotomized participants into CMC=0 (CMC−) vs. CMC>0 (CMC+) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEM), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and APOE effects.

RESULTS

CMC+ participants had significantly greater neurodegeneration than CMC− participants but did not differ by amyloid or ERC-tau. The SEM models showed that i) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and ii) vascular health specifically the presence of hyperlipidemia had a significant direct impact on ERC-tau.

INTERPRETATION

Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health.

Keywords: Alzheimer’s disease, Vascular Health, Amyloid, Tau, Neurodegeneration

Go to:

INTRODUCTION

Age is a significant driver of decline in vascular health1 and increase in Alzheimer’s disease pathophysiology (ADP)2. Several studies have shown that decline in vascular health has a significant impact on brain health and also increases the risk of AD dementia3–9. While it is well known that the impact of vascular health on cognitive performance is mediated via vascular brain injury6, 8, the direct impact of vascular health on each individual ADP process, namely amyloid, tau, and AD-associated neurodegeneration, is poorly understood and the interrelationships between ADP and vascular health are highly debated.

We hypothesized that the associations between ADP biomarkers and vascular risk factors can be disentangled by considering the direct and indirect effects of age, sex and APOE on each of these processes. Therefore, in this paper we aimed to investigate the association between age, vascular health, and ADP imaging biomarkers in a population-based elderly sample using two separate methods to understand these complex associations. In the first set of analyses, we evaluated the impact of vascular health on each of the AD biomarkers after accounting for the effects of age (both linear and non-linear). In the second set of analyses, we evaluated these associations by making assumptions about the sequence of AD biomarkers based on the widely accepted amyloid biomarker cascade10 which posits that amyloid deposition accelerates tau deposition which in turn drives neurodegeneration that underlies cognitive impairment. We undertook this second approach to capture the direct and indirect impact of age and vascular health on each of the ADP biomarkers.

The present study included Mayo Clinic Study of Aging (MCSA) participants who had ADP imaging biomarkers. In this paper, we considered the following main imaging surrogates of ADP – i) Amyloid-PET imaging using 11C-PiB-PET as a surrogate for cerebral amyloidosis11; ii) Tau-PET imaging using 18F-AV1451-PET (also known as T807 and flortaucepir) as a surrogate for abnormal 3R/4R tau deposition12; iii) Neurodegeneration in AD signature regions using MRI and FDG-PET as a surrogate for AD specific neuronal dysfunction13. We specifically looked at vascular health in the recent past i.e. in the 5 year time-period prior to the ascertainment of the ADP biomarkers.

Go to:

METHODS

Selection of Participants

All participants were enrolled in the MCSA, a population based study of Olmsted County, MN residents. The Olmsted County population was enumerated using the Rochester Epidemiology Project (REP) medical records -linkage system14, 15 which allowed us to ascertain vascular health factors from health care records instead of relying on self-report. We included all 430 elderly individuals (ages >60 years) with APOE genotype, vascular health indicators (discussed below), and concurrent imaging (PIB-PET, Tau-PET, and MRI scans). At the time of the scans, 389 were cognitively unimpaired, 33 had mild cognitive impairment, 5 were diagnosed with a neurodegenerative disorder (2 AD and 3 with mixed dementia), and 3 had a missing clinical diagnosis due to incomplete data. A subset of these individuals also had FDG-PET scans (n=329) which was included. The complete details of MCSA design and clinical diagnoses criteria were discussed by Petersen et al.16 and Roberts et al.17.

Standard protocol approvals, registrations, and patient consents

These studies were approved by the Mayo Clinic and Olmsted Medical Center institutional review board. Informed consent was obtained from all participants or their surrogates.

Demographics and APOE

Sex and years of education were obtained at the clinical visit. Age at the time of the MRI scan was considered. APOE genotype (presence of an APOE ε4 allele) was determined from blood collected at the clinical visit.

Cognitive Performance

The neuropsychological battery consisted of 9 tests covering 4 cognitive domains, as previously described16, 17. A global cognitive summary score was estimated from the z-transformation of the average of the four domain z-scores (executive function, language; memory, and visuospatial performance).

Vascular Health – Cardiovascular and Metabolic Conditions

The REP diagnostic indices were searched in a 5-year capture frame before the MCSA visit18, 19 to identify International Classification of Diseases, Ninth Revision (ICD-9) codes and Tenth Revision (ICD-10) codes associated with health care visits. Both ICD-9 (through Sept 2015) and ICD-10 (after Oct 2015) codes were pooled together by the REP under seven cardiovascular and metabolic conditions proposed by the U.S. Department of Health and Human Services in 2010 as indicators of vascular health20: hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke. The specific codes pooled together are tabulated in the supplemental material. In addition to using each individual component of vascular health separately, we also computed a composite score (referred here as CMC) which represents the summation of the presence or absence of each of these conditions. To reduce the false positive rates, we required that individuals received two codes for any given condition separated by more than 30 days within the 5-year capture period as done previously by REP investigators19, 20.

AD Imaging Biomarkers

Amyloid, Tau, and Neurodegeneration Assessment from PET scans

The acquisition and processing details of amyloid PET, Tau-PET, and FDG-PET scans acquired on the study participants were discussed in detail by Jack et al.21. For amyloid PET, we computed the global amyloid load for each subject by calculating median uptake in the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/precuneus regions of interest (ROIs) divided by the median uptake in the cerebellar crus gray matter ROI21. For Tau-PET, we assessed entorhinal cortex (ERC-tau) in each individual subject by calculating median uptake in the entorhinal cortex divided by the median uptake in the cerebellar crus and used it as a signature for AD related tau pathology22. We used ERC-tau because of two reasons – i) in our recent work we found that it was the most sensitive region to global amyloid deposition22 and ii) entorhinal cortex (and hippocampus) has increased vulnerablility to tau deposition2 as well as age related atrophy (in the absence of ADP)23 making it an ideal region for modeling the effects of age, vascular risk, and amyloid effects on tau. Since hippocampus has signal from choroid plexus we did not include hippocampus.

The FDG-PET summary in AD signature regions proposed previously24 were computed for each individual scan by averaging the left and right angular gyri, bilateral posterior cingulate and left middle/inferior temporal gyrus values normalized by the pons and vermis uptake.

AD-pattern Neurodegeneration Assessment from Structural MRI scans

MRI was acquired on two 3T General Electric (GE) scanners. Freesurfer version v 5.3 was used to estimate average cortical thickness in AD signature regions (entorhinal cortex, inferior temporal, middle temporal, fusiform) into a single measure which was used as surrogate for AD related neurodegeneration13.

Statistical Methods

Dichotomization by Presence of Risk Factor

Standard summary measures were used to describe characteristics for all participants and for strata determined by CMC=0 (CMC−) vs. CMC>0 (CMC+). The differences in demographic variables between CMC− vs. CMC+ groups were tested using ANOVA for the continuous variables and chi-square for the categorical variables. Since age is a significant driver for ADP, vascular health, and cognition, we adjusted for age via ANCOVA in the group comparisons for cognition and AD imaging biomarkers. We also report Cohen’s D based effect-sizes for all variables between the two groups. For AD biomarkers and global cognition summary score, Cohen’s D was calculated using age adjusted means and standard deviations. In addition, we performed analyses allowing for nonlinear age adjustments from spline curves with knots at 68, 74, and 82 years. We also tested the group differences between all participants dichotomized by the presence and absence of each of the CMC components i.e. hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke. We also conducted sensitivity analyses in only cognitively unimpaired individuals as well as after dichotomizing individuals based on the CMC<2 and CMC≥2.

Structural Equation Models

We conducted path analyses (structural equation models with only manifest, i.e. observed variables) using Mplus version 8.0 structural equations software and the R Lavaan package. Path analyses are extensions of regression models, and require a weak causal ordering of the variables to be specified before running any models. They allow us to account for complex relationships between the variables, rather than simply adjusting for confounding variables through ANCOVA. Assuming that the structure is correct (or close; there is reasonable robustness in these analyses), the SEM models should give a cleaner and more detailed picture of the effects. We first fit a saturated model with all possible associations between five levels of variables (plotted from left to right), where Level 1 consisted of sex, age at MRI, and APOE4 genotype, Level 2 consisted of the summary CMC measure (vascular health), Level 3 consisted of amyloid deposition, Level 4 consisted of ERC-tau, and Level 5 consisted of neurodegeneration. For the neurodegeneration variable, we only considered neurodegeneration in AD signature regions from MRI in the SEM models because we did not have FDG-PET scans in the full sample. Sex was added to the model because there are sex differences in the aging process25.

Each level in the SEM analysis is assumed to come later than preceding levels in a causal framework. Thus, any variable can cause changes to variables lying in higher levels. Any variables lying between variables on a lower and higher level are mediators. The possible causal associations are thus direct effects (arrow directly joins variables), indirect effects (arrows pass through one or more mediators), and total effects (sum of direct and indirect). We pruned the path analysis using goodness of fit measures (Bayesian Information criterion (BIC), chi-square test of model fit, root mean square error of approximation (RMSEA), Tucker-Lewis Index (TLI) and Comparative Fit Index (CFI)) and individual p-values until all paths in the final model were significant, and the goodness of fit measures indicated that the model fit the observed data well. We checked the pruning using lasso in the R package RegSEM26 and found that the pruned models were consistent. We report regression coefficients with their associated standard errors and p-values. The coefficients give the predicted change in the outcome (higher level) variable per unit increase in the predictor (lower level) variable. Age was coded to give results per 10-year (decade) increase. CMC units correspond to an increase of one condition. Amyloid deposition and ERC-tau were first log-transformed to better meet the model assumptions, and then standardized so that a unit increase corresponds to one standard deviation. Neurodegeneration was standardized so that a unit increase corresponds to one standard deviation and the sign was flipped such that high values are worse i.e. in the same direction as amyloid and tau. We also conducted a sensitivity SEM analysis using all seven indicators of vascular health as individual predictor variables.

Go to:

RESULTS

The overall participant characteristics as well as participants dichotomized by CMC are shown in Table 1. The CMC+ group was significantly older but did not differ by sex, APOE genotype, education, or global cognition from the CMC- group. Figure 1 shows the bar plots of mean number of CMC conditions and AD neuroimaging biomarkers by 5 year increments and illustrates the worsening of each of these variables with age. After age adjustment, amyloid and ERC-tau levels were not significantly different between the CMC+ and CMC− group. On the other hand, FDG-PET uptake and MRI cortical thickness were significantly lower between the CMC− and CMC+ groups. The relative differences between the groups were significantly greater for FDG and MRI in comparison to the amyloid and ERC-Tau levels as observed by the magnitude of the effect sizes. Since the association between vascular health and age is fairly linear, the more general analyses that allowed for nonlinear age adjustment produced very similar results for all biomarkers. In the sensitivity analyses with only cognitively unimpaired individuals (Supplemental Tables 1 and 2) and when all individuals were dichotomized by CMC=2 (Supplemental Table 3), we found similar conclusions.

Figure 1

Barplots of average vascular risk (CMC variables), amyloid deposition (PIB SUVr), tau deposition (ERC-Tau SUVr), and MRI neurodegeneration (average thickness in AD signature regions in mm) with 95% confidence intervals by 5-year increments.

Table 1

Study participants dichotomized by the presence/absence of cardiac and metabolic conditions (CMC). The mean (SD) are listed for the continuous variables and count (%) are listed for the categorical variables.

	All n = 430	No CMC n = 66	CMC n = 364	P-value	Cohen's D
Demographics‡
Age, yrs	74.7 (8.4)	70.0 (7.9)	75.5 (8.3)	<0.001	0.676
Range	60.0, 98.0	60.0, 94.0	60.0, 98.0
Males, no. (%)	240 (56%)	35 (53%)	205 (56%)	0.62	0.066
E4 Carrier, no. (%)	120 (28%)	15 (23%)	105 (29%)	0.31	0.136
Education, yrs	14.7 (2.6)	14.8 (2.4)	14.7 (2.6)	0.62	0.067
Range	7.0, 20.0	7.0, 19.0	7.0, 20.0
Cognition (zGlobal)†	0.15 (1.08)	0.54 (0.99)	0.07 (1.08)	0.17	0.187
Range	−3.82, 2.43	−2.62, 2.43	−3.82, 2.38
AD Imaging Biomarkers†
PIB Ratio, SUVr††	1.58 (0.43)	1.47 (0.32)	1.60 (0.45)	0.71	0.048
Range	1.13, 3.37	1.14, 2.81	1.13, 3.37
TAU ERC Ratio, SUVr††	1.13 (0.17)	1.08 (0.12)	1.14 (0.18)	0.36	0.12
Range	0.86, 2.15	0.91, 1.56	0.86, 2.15
FDG PET (AD Sig), SUVr	1.52 (0.15)	1.61 (0.18)	1.51 (0.14)	0.002	0.46
Range	1.09, 2.22	1.09, 2.22	1.15, 1.85
MRI (AD Sig), mm	2.83 (0.19)	2.92 (0.14)	2.81 (0.19)	0.050	0.256
Range	2.07, 3.23	2.51, 3.20	2.07, 3.23

‡P-values for the demographics variables are unadjusted and are from either an ANOVA model or chi-squared test for differences in proportions

†P-values for differences between groups come from an ANCOVA model adjusting for age

††These reported p-values are based on the log transformed values.

For the adjusted variables Cohen’s D was calculated using age adjusted means and standard deviations

FDG-PET was missing in 101 participants (No CMC: n=16; CMC>0: n=85) and zGlobal was missing in 44 participants (No CMC: n=4; CMC>0: n=40)

Supplemental Table 4 summarize the group differences for demographics and cognition between participants dichotomized by the presence and absence of each of the CMC components. Men had a greater frequency of cardiac arrhythmias and coronary artery disease. None of the CMC components were significantly associated with APOE4 carrier status. Education levels were significantly lower in individuals with stroke and congestive heart failure compared to those without these conditions. Cognition was significantly lower or approached significance for cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke but not for hyperlipidemia or hypertension.

Table 2 summarizes the AD biomarker results for all individuals when they were dichotomized by the presence and absence of each CMC component. For each of the CMC components, amyloid load was not significantly different between participants with and without the risk factor. ERC-tau was slightly higher in those with hyperlipidemia versus those without hyperlipidemia (p=0.070) as well as those with coronary artery disease and without coronary artery disease (p=0.075). Neurodegeneration biomarkers (FDG-PET and/or MRI) were significantly (p<0.05) worse for five of the seven vascular health indicators (hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, and diabetes). Supplemental Table 2 summarizes the results for only cognitively unimpaired individuals and shows similar results.

Table 2

AD imaging biomarkers in study participants dichotomized by the presence/absence of each of the cardiovascular metabolic components with the mean (SD).

Hyperlipidemia	Absent n= 150	Present n= 280	P-value	Cohen's D
PIB Ratio, SUVr††	1.55 (0.42)	1.59 (0.44)	0.82	0.022
TAU ERC Ratio, SUVr††	1.10 (0.13)	1.14 (0.19)	0.070	0.182
FDG PET (AD Sig), SUVr	1.56 (0.17)	1.50 (0.13)	0.013	0.286
MRI (AD Sig), mm	2.87 (0.16)	2.81 (0.20)	0.085	0.172
Hypertension	Absent n= 167	Present n= 263
PIB Ratio, SUVr††	1.54 (0.41)	1.60 (0.44)	0.92	0.01
TAU ERC Ratio, SUVr††	1.11 (0.16)	1.14 (0.17)	0.84	0.02
FDG PET (AD Sig), SUVr	1.55 (0.16)	1.51 (0.14)	0.19	0.145
MRI (AD Sig), mm	2.87 (0.17)	2.80 (0.19)	0.12	0.153
Cardiac Arrhythmias	Absent n= 324	Present n= 106
PIB Ratio, SUVr††	1.57 (0.43)	1.62 (0.44)	0.23	0.127
TAU ERC Ratio, SUVr††	1.12 (0.17)	1.15 (0.18)	0.96	0.005
FDG PET (AD Sig), SUVr	1.54 (0.14)	1.47 (0.15)	0.050	0.244
MRI (AD Sig), mm	2.86 (0.17)	2.74 (0.21)	0.005	0.298
Coronary Artery Disease	Absent n= 351	Present n= 79
PIB Ratio, SUVr††	1.56 (0.42)	1.67 (0.47)	0.92	0.012
TAU ERC Ratio, SUVr††	1.11 (0.16)	1.18 (0.20)	0.075	0.213
FDG PET (AD Sig), SUVr	1.54 (0.14)	1.46 (0.15)	0.032	0.29
MRI (AD Sig), mm	2.85 (0.17)	2.74 (0.23)	0.033	0.255
Stroke	Absent n= 402	Present n= 28
PIB Ratio, SUVr††	1.57 (0.42)	1.73 (0.55)	0.53	0.121
TAU ERC Ratio, SUVr††	1.13 (0.17)	1.16 (0.16)	0.94	0.014
FDG PET (AD Sig), SUVr	1.53 (0.15)	1.49 (0.17)	0.77	0.064
MRI (AD Sig), mm	2.83 (0.18)	2.77 (0.24)	0.94	0.014
Congestive Heart Failure	Absent n= 418	Present n= 12
PIB Ratio, SUVr††	1.57 (0.43)	1.79 (0.46)	0.32	0.288
TAU ERC Ratio, SUVr††	1.12 (0.17)	1.21 (0.20)	0.33	0.285
FDG PET (AD Sig), SUVr	1.52 (0.15)	1.51 (0.15)	0.78	0.109
MRI (AD Sig), mm	2.84 (0.18)	2.64 (0.24)	0.012	0.737
Diabetes	Absent n= 260	Present n= 170
PIB Ratio, SUVr††	1.54 (0.40)	1.64 (0.47)	0.12	0.153
TAU ERC Ratio, SUVr††	1.11 (0.15)	1.15 (0.20)	0.13	0.149
FDG PET (AD Sig), SUVr	1.56 (0.14)	1.46 (0.13)	<0.001	0.653
MRI (AD Sig), mm	2.86 (0.18)	2.79 (0.19)	0.001	0.316

Open in a separate window

P-values for differences between groups come from an ANCOVA model adjusting for age.

††These reported p-values are based on the log transformed values.

Cohen’s D was calculated using age adjusted means and standard deviations

The results of the significant associations in the path analyses are shown in Figure 2. The final model fit the data very well: The chi-square test of model fit (comparing to a saturated model) was not significant (p=0.24), the RMSEA (0.026) was less than 0.05, and the TLI (0.990) and CFI (0.996) were both greater than 0.95. Please note that the coefficients across all arrows cannot be compared but coefficients on arrows going to a particular outcome are comparable. These associations are split by paths to outcome variables (vascular health and AD biomarkers) in Figure 3. We have included Table 3 with the complete direct and indirect effects observed in the Figure 2. Here we describe the predictors of each of the outcomes in a stepwise fashion: 1) Age (coefficient=0.616) and being male (coefficient=0.287) were significant direct predictors of vascular health. 2) Age (coefficient=0.446) and APOE4 (coefficient=0.612) were significant direct predictors of amyloid deposition. 3) CMC and Amyloid were significant direct predictors of ERC-tau with the effect of amyloid on ERC-tau (coefficient=0.555) being larger than the effect of CMC on ERC-tau (coefficient=0.067). Age had both an indirect effect through CMC (coefficient=0.041, p=0.016) and an indirect effect through amyloid deposition (coefficient=0.247, p<0.001) on ERC-tau. 4) Age, sex, CMC, and ERC-tau were significant direct predictors of AD-pattern neurodegeneration. Age again had a large direct effect (coefficient=0.513) and smaller indirect effects through CMC (coefficient=0.057, p=0.002), CMC then ERC-tau (coefficient=0.009, p=0.029) and amyloid deposition then ERC-tau (coefficient=0.051, p<0.001) for a total effect coefficient of 0.630. Sex had a direct impact on AD-pattern neurodegeneration (coefficient=0.186), though the potential indirect paths through CMC and CMC then ERC-tau were not significant. CMC had both a direct effect (coefficient=0.093) and indirect effect through ERC-tau (coefficient=0.014, p=0.023) on AD-pattern neurodegeneration. ERC-tau had a direct effect (coefficient=0.207), and APOE4 had only an indirect effect (coefficient=0.070, p<0.001) on AD-pattern neurodegeneration through amyloid then ERC-tau.

Figure 2

Final Structural Equation Model along with significant associations shown by solid arrows. The standardized coefficients, standard errors (in brackets), and p-values are shown beside the arrows. The amyloid cascade is shown by the orange boxes. ND denotes neurodegeneration in AD regions on MRI.

Figure 3

Direct and Indirect pathways to (A) vascular health and each of the ADP biomarkers (B) Amyloid; (C) Tau; (D) ND or Neurodegeneration in AD regions on MRI

Table 3

Direct and Indirect effects seen in the final SEM model shown in Figure 2.

Type of effect	Path	Estimate (std. error)	p-value
Total	Age to CMC	0.616 (0.080)	<0.001
Direct	Age to CMC	0.616 (0.080)	<0.001
Total	Male to CMC	0.287 (0.136)	0.034
Direct	Male to CMC	0.287 (0.136)	0.034
Total	Age to Amyloid	0.446 (0.050)	<0.001
Direct	Age to Amyloid	0.446 (0.050)	<0.001
Total	APOE to Amyloid	0.612 (0.095)	<0.001
Direct	APOE to Amyloid	0.612 (0.095)	<0.001
Total	Age to Tau	0.289 (0.036)	<0.001
Total Indirect	Age to Tau	0.289 (0.036)	<0.001
Indirect	Age to Amyloid to Tau	0.247 (0.033)	<0.001
Indirect	Age to CMC to Tau	0.041 (0.017)	0.016
Total	Male to Tau	0.019 (0.012)	0.105
Indirect	Male to CMC to Tau	0.019 (0.012)	0.105
Total	APOE to Tau	0.340 (0.058)	<0.001
Indirect	APOE to Amyloid to Tau	0.340 (0.058)	<0.001
Total	CMC to Tau	0.067 (0.027)	0.012
Direct	CMC to Tau	0.067 (0.027)	0.012
Total	Amyloid to Tau	0.555 (0.040)	<0.001
Direct	Amyloid to Tau	0.555 (0.040)	<0.001
Total	Age to Neurodegeneration	0.630 (0.047)	<0.001
Direct	Age to Neurodegeneration	0.513 (0.050)	<0.001
Total Indirect	Age to Neurodegeneration	0.117 (0.023)	<0.001
Indirect	Age to Amyloid to Tau to Neurodegeneration	0.051 (0.012)	<0.001
Indirect	Age to CMC to Neurodegeneration	0.057 (0.018)	0.002
Indirect	Age to CMC to Tau to Neurodegeneration	0.009 (0.004)	0.029
Total	Male to Neurodegeneration	0.216 (0.078)	0.006
Direct	Male to Neurodegeneration	0.186 (0.077)	0.016
Total Indirect	Male to Neurodegeneration	0.031 (0.017)	0.064
Indirect††	Male to CMC to Neurodegeneration	0.013 (0.007)	0.072
Indirect††	Male to CMC to Tau to Neurodegeneration	0.002 (0.001)	0.120
Total	APOE to Neurodegeneration	0.070 (0.018)	<0.001
Indirect	APOE to Amyloid to Tau to Neurodegeneration	0.070 (0.018)	<0.001
Total	CMC to Neurodegeneration	0.107 (0.028)	<0.001
Direct	CMC to Neurodegeneration	0.093 (0.027)	0.001
Indirect	CMC to Tau to Neurodegeneration	0.014 (0.006)	0.023
Total	Amyloid to Neurodegeneration	0.115 (0.024)	<0.001
Indirect	Amyloid to Tau to Neurodegeneration	0.115 (0.024)	<0.001
Total	Tau to Neurodegeneration	0.207 (0.040)	<0.001
Direct	Tau to Neurodegeneration	0.207 (0.040)	<0.001

Open in a separate window

††These indirect effects are not in the final model; coefficients and p-values are from the saturated model.

The results of the sensitivity SEM analysis results with all seven indicators of vascular health are shown in Figure 4. The final model in this case fit the data fairly well: The RMSEA (0.055) was close to 0.05, and the TLI (0.894) and CFI (0.929) were both close to 0.90, though below 0.95. The chi-square test in this model does not apply in the usual manner. Simple theoretically reasonable additions to the model did not appreciably improve the fit. Of the seven variables, diabetes, cardiac arrhythmias, congestive heart failure, and hyperlipidemia were significant predictors of AD biomarkers. Among these, only hyperlipidemia was a significant predictor of ERC-tau and the rest were significant predictors of neurodegeneration. None of the vascular health indicators were significant predictors of amyloid deposition.

Figure 4

Final Structural Equation Model with each individual indicator of vascular health along with significant associations shown by solid arrows. The standardized coefficients, standard errors (in brackets), and p-values are shown beside the arrows. The amyloid cascade is shown by the orange boxes. ND denotes neurodegeneration in AD regions on MRI. CHF denotes congestive heart failure.

Go to:

DISCUSSION

The main findings of this paper were that i) poor vascular health does not significantly impact amyloid deposition but has a significant direct and indirect effect on AD neurodegeneration in an elderly sample; and ii) there was a significant impact of vascular health on ERC-tau that was driven by hyperlipidemia but the effect was smaller than the association of amyloid with ERC-tau.

Age is a significant predictor for vascular health as observed in Figure 1 and ​and2.2. Aging acts through a number of biological mechanisms at the cellular or tissue level that may lead to multi-system loss of reserve and function as discussed by Fabbri et al27. This multi-system homeostatic dysregulation leads to several chronic diseases including cardiovascular and metabolic conditions27, 28. Age is also a significant predictor for brain changes. Amyloid and tau pathologies2 as well as brain shrinkage (even without AD pathologies)23 increase with age. Therefore, accounting for age in the first set of analyses (Tables 1 and ​and2)2) allowed us to understand if vascular health and ADP were associated independently of the impact of age on each of these factors. Additionally, the SEM analyses allowed us to simultaneously look at the direct and indirect effects of age on each of the variables of interest and also take into consideration the step-wise progression of AD processes that is not possible with group comparisons.

Predictors of Vascular Health

In addition to age, being male was a significant predictor of vascular health (Figure 2 and ​and3A).3A). As seen in supplemental tables, there was a greater frequency of men among those with cardiac arrhythmias and coronary artery disease consistent with the literature29 and this may have driven the path from sex to vascular health. In both the sets of analyses, we did not find an association between APOE4 and vascular health.

Predictors of Amyloid Deposition

As expected, APOE4 along with age were significant predictors of amyloidosis30 in Figure 2 and ​and3B.3B. In both the analyses, we did not find an association between poor vascular health and amyloid deposition. In the SEM analyses (Figure 2) and Table 1, we specifically tested if vascular health has an impact on amyloid and did not find evidence for an association. In the sensitivity SEM analysis (Figure 4) as well as Table 2, we also tested the impact of each vascular health indicator on amyloid deposition and did not find evidence for an association between vascular health and amyloid deposition. These results are consistent with a systematic review by Chui et. al. that showed that there is insufficient evidence to support that vascular risk increases amyloid pathology5. One major issue that may have contributed to the debate in the literature could be the confounding effect of age seen on both vascular health and AD biomarker variables. Amyloid accumulation in the brain is due to the imbalance between amyloid production and clearance. While we found no significant association between vascular health and amyloid accumulation in early stages of the disease, this does not preclude the possibility that in later stages of the disease both processes may interact through mechanisms such as poor clearance of extracellular Aβ through the glymphatic system31, 32 or large extent of hypoperfusion and hypoxia contributing to greater amyloid accumulation33.

Predictors of Tau Deposition

Amyloid was the strongest predictor of ERC-tau as expected10. We also found evidence for an amyloid independent direct pathway from CMC to ERC-tau (Figure 2 and ​and3C).3C). In Table 2, we found weak associations between vascular health and tau deposition as suggested by the group differences seen with hyperlipidemia (p=0.07) and coronary artery disease (p=0.075). From the sensitivity SEM analyses in Figure 4, we found that the primary predictor of the association between vascular health and ERC-tau seen in Figure 2 was hyperlipidemia. In our recent study34 as well as this paper, we found evidence that lipids play an important role in the pathogenesis of processes upstream to AD neurodegeneration. Using Tau-PET and amyloid PET together here, we were able to further discern that tau deposition is specifically influenced by hyperlipidemia. Cholesterol accumulation and impaired cholesterol metabolism has been found to be toxic to neuronal cells and proposed to be involved in the generation of tau35. Additionally, Statins have been shown to be reduce the neurofibrillary tangle burden in animal models36, 37 and modulate tau phosphorylation in humans38, 39. Though we found a small effect of poor vascular health, specifically hyperlipidemia on tau deposition, further longitudinal studies are needed to clarify the mechanisms through which these risk factors may increase tau deposition and will be the focus of our future studies.

We did not detect a direct pathway from age to tau consistent with the primary age-related tauopathy (PART) hypothesis40. The effect of age on ERC-tau is much smaller compared to the effect of amyloid on ERC-tau since PART (abnormal tau in the absence of amyloidosis) is observed only in advanced ages compared to ages at which abnormal amyloid and tau are observed and in only a smaller proportion of elderly (compared to elderly with both amyloid and tau pathologies). Since our model structure forces amyloid to come before tau, this could possibly overwrite any direct effect of age especially if the direct effect is small relative to the amyloid effect.

Predictors of Neurodegeneration

Age, being male, ERC-tau, and poor vascular health had a significant direct impact on neurodegeneration. Age (even without amyloid) and being male has been shown to be associated with neurodegeneration23. Animal models support that there is age-related neural structure alteration specifically reductions in spine density and reductions in neuronal arborization that reflects early neurodegeneration41, 42. Tau deposition and neurodegeneration are well known to be tightly coupled10. While studies show that poor vascular health is associated with increased risk of Alzheimer’s disease43, 44 as well as neurodegeneration45, 46, we found evidence for a significant direct and indirect impact of vascular health on AD neurodegeneration that was not mediated by amyloid deposition. This suggests that vascular health lowers the threshold for dementia by independently impacting neurodegeneration and to some extent ERC-tau but has minimal direct impact on amyloidosis5, 47. In Figure 4, we found that among all the variables, the primary predictors of neurodegeneration among the CMC variables were congestive heart failure, diabetes, and cardiac arrhythmias.

Each of the AD biomarkers (tau deposition, amyloid deposition, and neurodegeneration) can be initiated independently but there is sufficient evidence supporting the AD biomarker cascade hypothesis that amyloid deposition accelerates tau deposition, which in turn, is closely associated with neurodegeneration and cognitive decline in AD. An important point to consider is that we included the complete spectrum of population based individuals for the SEM models. If we had included only cognitively unimpaired individuals, we would be excluding individuals in whom there was sufficient pathology (due to amyloid, tau, neurodegeneration, as well as vascular risk factors) to cause cognitive impairment which would create significant bias when modeling the entire disease process. Though we did not test the biomarker cascade hypothesis but assumed a fixed ordering in this paper, we found evidence for the step-wise association of amyloid on ERC-tau and ERC-tau on AD-pattern neurodegeneration. We conducted additional sensitivity analyses and found that i) amyloid and tau at the same level had a poor model fit and ii) tau before amyloid resulted in a model with no direct or indirect effect of amyloid on neurodegeneration, providing support for the ordering we assumed in the paper. The SEM approach we took here was valuable because it allowed us to investigate the independent impact of vascular health on AD biomarkers after accounting for the interrelationships between age and AD biomarkers as well as the between each of the AD biomarkers.

Strengths and Limitations

A major strength of this study is the availability of electronic health records through the REP from which our MCSA study participants are sampled and also allowed us to ascertain vascular health prior to the scans. While the use of health care records might be considered a limitation, the requirement of two clinical visits separated by 30 days limits false positives, as well as previous papers that validated REP based ICD-9 codes support the ascertainment of vascular health from REP based health care records48–51. There were also other limitations to this study. We only focused on an amyloid sensitive tau region seen in the elderly22. The results may be different for Tau-PET uptake in different regions and in atypical AD. We also undertook a global approach here with cross-sectional (vascular health) diagnosis data instead of looking at the mechanistic underpinnings of each vascular health indicator along with blood serum biomarkers9, 52and studying these predictors and outcomes in a longitudinal framework to further understand the casual associations. However, we strongly believe that such a birds-eye view is important and will be helpful in guiding the development of future hypotheses.

Go to:

Supplementary Material

Supp info

Click here to view.(42K, docx)

Go to:

Acknowledgments

We thank all the study participants and staff in the Mayo Clinic Study of Aging, Mayo Alzheimer’s Disease Research Center, and Aging Dementia Imaging Research laboratory at the Mayo Clinic for making this study possible. We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. We would also like to thank Jeremiah Aakre, MS with help with the ICD codes.

This work was supported by NIH grants R01 NS097495 (PI: Vemuri), R01 AG56366 (PI: Vemuri), U01 AG06786 (PI: Petersen), P50 AG16574/P1 (PI: Vemuri), P50 AG16574 (PI: Petersen), R01 AG11378 (PI: Jack), R01 AG41851 (PIs: Jack and Knopman); the GHR Foundation grant, the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Foundation, Liston Award, Elsie and Marvin Dekelboum Family Foundation, Schuler Foundation, Opus building NIH grant C06 RR018898, and was made possible by Rochester Epidemiology Project (R01 AG034676). The funding sources were not involved in the manuscript review or approval.

Go to:

Footnotes

Author Contributions

Study Concept and Design: PV, TGL, SAP; Data Acquisition, Analysis, and interpretation of the data: PV, TGL, SAP, DSK, VJL, JGR, ROR, MMM, MMM, RCP, CRJ; Drafting of the manuscript and figures: PV, TGL, SAP.

Potential Conflicts of Interest

The authors do not any pertinent disclosures relevant to this study.

Go to:

References

1. Sawabe M. Vascular aging: from molecular mechanism to clinical significance. Geriatrics & gerontology international. 2010;10(s1):S213–S20. [PubMed]

2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59. [PubMed]

3. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009 Jan 27;72(4):368–74. [PMC free article] [PubMed]

4. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010 Sep;120(3):287–96. [PMC free article] [PubMed]

5. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther. 2012;4(1):1. [PMC free article][PubMed]

6. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol. 2001 Apr;58(4):643–7. [PubMed]

7. Kivipelto M, Helkala E-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Bmj. 2001;322(7300):1447–51. [PMC free article][PubMed]

8. Knopman DS, Griswold ME, Lirette ST, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke. 2015 Feb;46(2):433–40. [PMC free article] [PubMed]

9. Villeneuve S, Reed BR, Madison CM, et al. Vascular risk and Abeta interact to reduce cortical thickness in AD vulnerable brain regions. Neurology. 2014 Jul 1;83(1):40–7. [PMC free article] [PubMed]

10. Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet neurology. 2013 Feb;12(2):207–16.[PMC free article] [PubMed]

11. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008 Jun;131(Pt 6):1630–45.[PMC free article] [PubMed]

12. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016 Jun 13;4(1):58. [PMC free article] [PubMed]

13. Jack CR, Jr, Wiste HJ, Weigand SD, et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain : a journal of neurology. 2015 Dec;138(Pt 12):3747–59. [PMC free article] [PubMed]

14. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clinic Proceedings. 2012;87(12):1202–13. [PMC free article] [PubMed]

15. St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012 Dec;41(6):1614–24. [PMC free article][PubMed]

16. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010 Sep 7;75(10):889–97. [PMC free article][PubMed]

17. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58–69.[PMC free article] [PubMed]

18. Vassilaki M, Aakre JA, Cha RH, et al. Multimorbidity and Risk of Mild Cognitive Impairment. J Am Geriatr Soc. 2015 Sep;63(9):1783–90. [PMC free article] [PubMed]

19. Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined american population: patterns by age, sex, and race/ethnicity. Mayo Clinic Proceedings. 2014 Sep 9;89(10):1336–49. [PMC free article] [PubMed]

20. Rocca WA, Gazzuola Rocca L, Smith CY, et al. Bilateral Oophorectomy and Accelerated Aging: Cause or Effect? J Gerontol A Biol Sci Med Sci. 2017 Feb 28; [PMC free article] [PubMed]

21. Jack CR, Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017 Mar;13(3):205–16. [PMC free article] [PubMed]

22. Vemuri P, Lowe VJ, Knopman DS, et al. Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst) 2017;6:21–30. [PMC free article] [PubMed]

23. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Progress in neurobiology. 2014 Jun;117:20–40. [PMC free article] [PubMed]

24. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010 Jul 20;75(3):230–8. [PMC free article] [PubMed]

25. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37–48. [PMC free article] [PubMed]

26. Jacobucci R, Grimm KJ, McArdle JJ. Regularized Structural Equation Modeling. Structural equation modeling: a multidisciplinary journal. 2016;23(4):555–66. [PMC free article] [PubMed]

27. Fabbri E, Zoli M, Gonzalez-Freire M, Salive ME, Studenski SA, Ferrucci L. Aging and Multimorbidity: New Tasks, Priorities, and Frontiers for Integrated Gerontological and Clinical Research. Journal of the American Medical Directors Association. 2015 Aug 1;16(8):640–7. [PMC free article][PubMed]

28. Ferrucci L, Studenski S. Chapter 72. Clinical Problems of Aging. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J, editors. Harrison's Principles of Internal Medicine, 18e. New York, NY: McGraw-Hills; 2012.

29. Manolio TA, Furberg CD, Rautaharju PM, et al. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. Journal of the American College of Cardiology. 1994;23(4):916–25. [PubMed]

30. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015 May 19;313(19):1924–38. [PMC free article] [PubMed]

31. Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Annals of neurology. 2014 Dec;76(6):845–61. [PMC free article] [PubMed]

32. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Science translational medicine. 2012 Aug 15;4(147):147ra11. [PMC free article] [PubMed]

33. Kitaguchi H, Tomimoto H, Ihara M, et al. Chronic cerebral hypoperfusion accelerates amyloid β deposition in APPSwInd transgenic mice. Brain research. 2009;1294:202–10. [PubMed]

34. Vemuri P, Knopman DS, Lesnick TG, et al. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA neurology. 2017 Apr 17;[PMC free article] [PubMed]

35. Leoni V, Solomon A, Kivipelto M. Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment. Biochemical Society transactions. 2010 Aug;38(4):1021–5. [PubMed]

36. Boimel M, Grigoriadis N, Lourbopoulos A, et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. Journal of neuropathology and experimental neurology. 2009 Mar;68(3):314–25. [PubMed]

37. Lu F, Li X, Suo AQ, Zhang JW. Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin. Chinese medical journal. 2010 Jul;123(14):1864–70.[PubMed]

38. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007 Aug 28;69(9):878–85. [PubMed]

39. Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer's disease : JAD. 2006 Dec;10(4):399–406. [PubMed]

40. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta neuropathologica. 2014 Dec;128(6):755–66.[PMC free article] [PubMed]

41. Yeoman M, Scutt G, Faragher R. Insights into CNS ageing from animal models of senescence. Nature reviews Neuroscience. 2012 Jun;13(6):435–45. [PubMed]

42. Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron. 2013 Jan 23;77(2):219–34. [PMC free article] [PubMed]

43. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009 Mar;66(3):300–5. [PMC free article] [PubMed]

44. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005 Oct;62(10):1556–60. [PubMed]

45. Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res. 2013 Jul;10(6):642–53. [PubMed]

46. Vassilaki M, Aakre JA, Mielke MM, et al. Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology. 2016 May 31;86(22):2077–84. [PMC free article] [PubMed]

47. Vemuri P, Knopman DS. The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochim Biophys Acta. 2016 May;1862(5):952–6. [PMC free article] [PubMed]

48. Leibson CL, Brown AW, Ransom JE, et al. Incidence of traumatic brain injury across the full disease spectrum: a population-based medical record review study. Epidemiology (Cambridge, Mass) 2011 Nov;22(6):836–44. [PMC free article] [PubMed]

49. Leibson CL, Naessens JM, Brown RD, Whisnant JP. Accuracy of hospital discharge abstracts for identifying stroke. Stroke. 1994 Dec;25(12):2348–55. [PubMed]

50. Leibson CL, Needleman J, Buerhaus P, et al. Identifying in-hospital venous thromboembolism (VTE): a comparison of claims-based approaches with the Rochester Epidemiology Project VTE cohort. Medical care. 2008 Feb;46(2):127–32. [PubMed]

51. Roger VL, Killian J, Henkel M, et al. Coronary disease surveillance in Olmsted County objectives and methodology. Journal of clinical epidemiology. 2002 Jun;55(6):593–601. [PubMed]

52. Leritz EC, Salat DH, Williams VJ, et al. Thickness of the human cerebral cortex is associated with metrics of cerebrovascular health in a normative sample of community dwelling older adults. NeuroImage. 2011 Feb 14;54(4):2659–71. [PMC free article] [PubMed]